GE Healthcare Technologies Inc (GEHC – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Craig Bijou from Bank of America Securities maintained a Hold rating on the stock and has a $97.00 price target.
Craig Bijou has given his Hold rating due to a combination of factors impacting GE Healthcare Technologies Inc. One significant consideration is the ongoing US-China trade tensions, which have been a major headwind for the company. Although there has been a recent softening in the US administration’s stance, the tariffs are still expected to affect GEHC’s earnings per share (EPS) significantly, with a potential 20% annualized hit already anticipated by investors.
Additionally, GEHC’s exposure to tariffs is notable, as it was one of the few medtech companies to include this impact in its 2025 guidance. The tariffs on imports from China, which account for a substantial portion of GEHC’s cost of goods sold (COGS), could lead to a 13% EPS reduction. Furthermore, retaliatory actions by China, such as export restrictions on rare earth elements and anti-dumping investigations, pose additional risks. Given these uncertainties and the need for more clarity on tariff impacts, Bijou maintains a Neutral stance until further visibility is obtained.
Based on the recent corporate insider activity of 59 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of GEHC in relation to earlier this year.